CytoDyn, Inc. is preparing for its next clinical trial of Cytolin, the breakthrough drug for HIV/AIDS that uses the body's own immune system to fight the virus. The preparations come at a time when CytoDyn, Inc. is making big changes that include relocating to a larger facility to accommodate expanded business activities.
(PRWEB) October 22, 2008 -- Although HIV and AIDS are substantially more treatable now than during the height of the AIDS epidemic in the 1980s, numerous challenges still face AIDS and HIV patients and AIDS researchers. One major concern is that drug-resistant strains of HIV are emerging globally, but there is hope that Cytolin, a first-in-class AIDS and HIV treatment from CytoDyn, Inc., can help address this problem.
A new clinical trial to reinvestigate dosing specifications for Cytolin will be conducted in San Francisco, California, by Dr. Jay Lalezari, a leading AIDS researcher. The study will be managed by New York City-based Target Health, Inc., which CytoDyn, Inc. has retained to serve as its contract research organization for the project.
Cytolin is based on a decade of progress in immunology. Community physicians used the drug experimentally at the height of the AIDS epidemic to rescue patients when no effective antiviral treatments had yet been approved for people with AIDS.
"We're excited about the progress we've made in preparing for the next clinical trial of Cytolin," explains Dr. Nadar Pourhassan, Chief Operating Officer of CytoDyn, Inc. "We should soon be prepared to show those unfamiliar with a decade of progress in immunology that science has the solution to multi-drug resistance in HIV/AIDS and, perhaps, other infectious diseases."
Cytolin is a unique treatment for AIDS
Copyright©2008 Vocus, Inc.
All rights reserved